

July 31, 2013

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (AB-44) ULOCUPLUMAB
 PRONUNCIATION ue" loe kup' lue mab
 THERAPEUTIC CLAIM Hematologic malignancies

CHEMICAL NAMES

Immunoglobulin G4-kappa, anti-[human C-X-C chemokine receptor type 4 (FB22, fusin, HM89, LCR1, NPYRL, CD184)], *Homo sapiens* monoclonal antibody; gamma 4 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-48*02 (96.9%)-(IGHD)-IGHJ6*01 [8.8.18] (1-125)-des-CH3K¹⁰⁷-IGHG4*01 (126-451)], (139-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (98.9%)-IGKJ1*01) [6.3.9] (1'-107')-IGKC*01 (108'-214')]; dimer (231-231":234-234")-bisdisulfide

STRUCTURAL FORMULA

Heavy chain

EVQLVESGGG	LVQPPGSLRL	SCAAAGFTFS	SYSMNWVRQA	PGKGLEWVSY	50
ISSRSRTIYY	ADSVKGRFTI	SRDNAKNSLY	LQMNSLRDED	TAVYYCARDY	100
GGQPPYYYY	GMDVWGQGT	VTVSSASTKG	PSVFPLAPCS	RSTSESTAAL	150
GCLVKDYFPE	PVTVSWNSGA	LTSGVHTFPA	VLQSSGLYSL	SSVVTVPSSS	200
LGTKTYTCNV	DHKPSNTKVD	KRVESKYGPP	CPPCPAPEFL	GGPSVFLFPP	250
KPKDTLMISR	TPEVTCVVD	VSQEDPEVQF	NWYVDGVEVH	NAKTKPREEQ	300
FNSTYRVVSV	LTVLHQDWLN	GKEYKCKVSN	KGLPSSIEKT	ISKAKGQPRE	350
PQVYTLPPSQ	EEMTKNQVSL	TCLVKGFYPS	DIAVEWESNG	QPENNYKTP	400
PVLDSGGSFF	LYSRLTVDKS	RWQEGNVFSC	SVMHEALHNN	YTQKSLSLSL	450
G					451

Light chain

DIQMTQSPSS	LSASVGDRV	ITCRASQGIS	SWLAWYQQKP	EKAPKSLIYA	50'
ASSLQSGVPS	RFSGSGSGTD	FITLTISLQ	EDFVITYCQQ	YNSYPRTFGQ	100'
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSK	STYSLSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges

22-96	22"-96"	23'-88'	23"-88"	134'-194'	134"-194"	139'-214'	139"-214"
152-208	152"-208"	231-231"	234-234"	266-326	266"-326"	372-430	372"-430"

Glycosylation sites (N)

Asn-302 Asn-302"

MOLECULAR FORMULA C₆₄₈₆H₉₉₆₀N₁₇₂₀O₂₀₄₆S₄₆
 MOLECULAR WEIGHT 146.2 kDa
 TRADEMARK None as yet
 SPONSOR Bristol-Myers Squibb
 CODE DESIGNATIONS MDX-1338, BMS-936564

CAS REGISTRY NUMBER 1375830-34-4

WHO NUMBER 9854

gbk